MedPath

Phosphate Metabolites in Brain of Humans Aged 50+

Not Applicable
Completed
Conditions
Basic Science
Registration Number
NCT03541473
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

The objective of this research project is to determine in elderly subjects (\>50 year old) by 31P-MRS the brain concentration of phosphorous metabolites species and fluxes, before and after consumption of 2 commercially available oral nutrition products

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Men and women aged between 50 and 75 years
  • Healthy, based on the medical screening visit
  • Normal BMI for age (18.5-29.9 kg/m2)
  • Able to understand and to sign a written informed consent prior to trial entry
  • Informed consent signed
Exclusion Criteria
  • Known type 1 or type 2 diabetes, on anamnesis

  • Family history of type 2 diabetes (parents)

  • Any other metabolic disease possibly impacting the postprandial glucose and insulin response (on anamnesis, to the opinion of the medical expert)

  • Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc, to the opinion of the medical expert

  • Any ongoing medication impacting dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid lowering medications, or fibrates , to the opinion of the medical expert

  • Any ongoing medication impacting the postprandial glucose and insulin response (like beta blockers), to the opinion of the medical expert

  • Any ongoing medication impacting brain metabolism or function (neuroleptics, antidepressants, anti-epileptics), to the opinion of the medical expert

  • Ongoing chemotherapy

  • Any food supplement intake (e.g. MCT, ketone salts = Calcium, Sodium, Potassium, Magnesium) or special diet (e.g. ketogenic diet) possibly impacting basal ketone levels, to the opinion of the medical expert.

  • Claustrophobia

  • Hearing disorders (the participant placed into the MRS tunnel should be able to hear from the operators, for safety purpose)

  • Having any metallic, electronic, magnetic, or mechanical implants, devices, or objects, for safety reason linked to magnetic field exposure (MRS):

    • Aneurysm clip(s)
    • Cardiac pacemaker
    • Implanted cardioverter defibrillator (ICD)
    • Electronic implant or device
    • Magnetically-activated implant or device
    • Neurostimulation system
    • Spinal cord stimulator
    • Cochlear implant or implanted hearing aid
    • Insulin or infusion pump
    • Implanted drug infusion device, like portacath® for instance
    • Any type of prosthesis or implant
    • Artificial or prosthetic limb
    • Any metallic fragment or foreign body
    • Hearing aid
    • Other implant
  • Subject injured by a metallic object or foreign body

  • Allergy to cow milk or soy proteins

  • Currently participating or having participated in an investigational trial during the past month

  • Subjects not willing and/or not able to comply with scheduled visits and the requirements of the research protocol.

  • Subject having a hierarchical link with the investigator or co-investigators.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
The change in brain NAD+/NADH ratio (RX) after the intake of the nutrition products31P metabolites and fluxes will be measured during one hour 2 times, one before product intake (control) and the second one 45 min after product intake"
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

École Polytechnique Fédérale de Lausanne (EPFL) / Center for Biomedical Imaging (CIBM)

🇨🇭

Lausanne, Switzerland

École Polytechnique Fédérale de Lausanne (EPFL) / Center for Biomedical Imaging (CIBM)
🇨🇭Lausanne, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.